Translational Research on Irreversible Electroporation: VX2 Rabbit Head and Neck



Head and neck cancers account for a small percent of new cancer cases each year in comparison to other cancers. However, the diagnosis of this disease is usually life threatening and negatively impacts the quality of the patient’s life. With various treatments or therapies available for the different stages of squamous cell carcinoma of the head and neck (SCCHN), the most prominent type of head and neck cancer, significant side effects or disadvantages such as severe toxicity and lack of organ preservation sometimes outweigh the positive outcomes. Irreversible electroporation (IRE) is a novel treatment that is currently showing promise in tumor ablation without the disadvantages of other techniques. Therefore, current research is underway in order to utilize IRE against implanted VX2 rabbit tumors in the head and neck region to demonstrate its effectiveness. Through preliminary results, positive outcomes are showing great promise that IRE may be the next innovative treatment for SCCHN.


Irreversible electroporation VX2 Head and neck cancer Squamous cell carcinoma of the head and neck Chemo-radiotherapy Epidermal growth factor receptor 


  1. 1.
    Gold KA, Lee HY, Kim ES. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer. 2009;115(5):922–35.PubMedCrossRefGoogle Scholar
  2. 2.
    Osaki T, Hirota J, Yoneda K, Yamamoto T, Ueta E. Distribution of surviving tumor cells after chemoradiotherapy in tongue and floor of mouth carcinomas. Head Neck. 1994;16(3):218–26.PubMedCrossRefGoogle Scholar
  3. 3.
    Batsakis JG. Surgical excision margins: a pathologist’s perspective. Adv Anat Pathol. 1999;6(3):140–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Woolgar JA. T2 carcinoma of the tongue: the histopathologist’s perspective. Br J Oral Maxillofac Surg. 1999;37(3):187–93.PubMedCrossRefGoogle Scholar
  5. 5.
    Jain P, Kumar P, Pai VR, Parikh PM. Neoadjuvant chemotherapy or chemoradiotherapy in head and neck cancer. Indian J Cancer. 2008;45(3):83–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43–66.PubMedCrossRefGoogle Scholar
  7. 7.
    Lango MN. Multimodal treatment for head and neck cancer. Surg Clin North Am. 2009;89(1):43–52; viii.Google Scholar
  8. 8.
    Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92(9):709–20.PubMedCrossRefGoogle Scholar
  9. 9.
    Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol. 2007;4(3):156–71.PubMedCrossRefGoogle Scholar
  10. 10.
    Kim ES, Kies M, Herbst RS. Novel therapeutics for head and neck cancer. Curr Opin Oncol. 2002;14(3):334–42.PubMedCrossRefGoogle Scholar
  11. 11.
    Vokes EE et al. Head and neck cancer. N Engl J Med. 1993;328(3):184–94.PubMedCrossRefGoogle Scholar
  12. 12.
    Lee JJ, Hah JH, Im SA, Kim SY, Sung MW, Kim KH, et al. Neoadjuvant chemotherapy followed by limited surgery in a mouse model of head and neck cancer. Anticancer Res. 2009;29(1):255–9.PubMedGoogle Scholar
  13. 13.
    Gilbert RW. Innovation in the surgical management of head and neck tumors. Hematol Oncol Clin North Am. 2008;22(6):1181–91; viii-ix.Google Scholar
  14. 14.
    Crile G. Landmark article Dec 1, 1906: excision of cancer of the head and neck. With special reference to the plan of dissection based on one hundred and thirty-two operations. By George Crile. JAMA. 1987;258(22):3286–93.PubMedCrossRefGoogle Scholar
  15. 15.
    Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355(9208):949–55.PubMedGoogle Scholar
  16. 16.
    Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer. 2004;11(4):689–708.PubMedCrossRefGoogle Scholar
  17. 17.
    Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA. 2007;298(1):70–82.PubMedCrossRefGoogle Scholar
  18. 18.
    Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78.PubMedCrossRefGoogle Scholar
  19. 19.
    Maor E, Ivorra A, Leor J, Rubinsky B. Irreversible electroporation attenuates neointimal formation after angioplasty. IEEE Trans Biomed Eng. 2008;55(9):2268–74.PubMedCrossRefGoogle Scholar
  20. 20.
    Rubinsky J, Onik G, Mikus P, Rubinsky B. Optimal parameters for the destruction of prostate cancer using irreversible electroporation. J Urol. 2008;180(6):2668–74.PubMedCrossRefGoogle Scholar
  21. 21.
    Bertacchini C, Margotti PM, Bergamini E, Lodi A, Ronchetti M, Cadossi R. Design of an irreversible electroporation system for clinical use. Technol Cancer Res Treat. 2007;6(4):313–20.PubMedGoogle Scholar
  22. 22.
    Onik G, Mikus P, Rubinsky B. Irreversible electroporation: implications for prostate ablation. Technol Cancer Res Treat. 2007;6(4):295–300.PubMedGoogle Scholar
  23. 23.
    Lee EW, Chen C, Prieto VE, Dry SM, Loh CT, Kee ST. Advanced hepatic ablation technique for ­creating complete cell death: irreversible electroporation. Radiology. 2010;255(2):426–33.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Division of Interventional Radiology, Department of RadiologyDavid Geffen School of Medicine at UCLALos AngelesUSA

Personalised recommendations